Skip to main content
Medicure Inc logo

Medicure Inc — Investor Relations & Filings

Ticker · MPH ISIN · CA58469E4085 LEI · 9845007T999BF377B627 TSXV Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2021-02-23 Regulatory Filings
Country CA Canada
Listing TSXV MPH

About Medicure Inc

https://www.medicure.com/

Medicure Inc. is a value-based pharmaceutical company specializing in the research, clinical development, and commercialization of human therapeutics. The company is primarily focused on developing and commercializing innovative and affordable medicines within the cardiovascular therapeutic area. Medicure's core mission is to serve patients by delivering safe and efficacious life-changing medicines, with a strategic focus on the U.S. market. It aims to offer a growing portfolio of products and services, ensuring patient access to necessary care.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-02-23 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a press release announcing Medicure Inc.'s participation in a virtual non-deal roadshow hosted by Renmark Financial Communications. It mentions an upcoming investor presentation and a live Q&A session. There is no actual financial data, report, or detailed presentation content included in the text. The document is short (3317 characters) and serves as an announcement of an event related to investor communication rather than the investor presentation itself or any formal financial report. Therefore, it fits best under the category of Investor Presentation (IP) as it focuses on the upcoming detailed presentation for investors.
2021-02-04 English
News release - English.pdf
Regulatory Filings
2021-01-27 English
News release - English.pdf
Regulatory Filings
2021-01-07 English
Material change report - English.pdf
M&A Activity Classification · 95% confidence The document is titled 'Material Change Report' and references compliance with National Instrument 51-102, which is a Canadian regulatory requirement for disclosure of material changes by public companies. The content describes a definitive agreement to acquire another company, Marley Drug, including financial details of the acquisition and strategic rationale. It is a formal announcement of a significant corporate event (an acquisition) rather than a full merger filing or tender offer document. The document is not a full annual or interim report, audit report, or earnings release. It is not a proxy, voting result, or remuneration report. The focus is on the acquisition transaction announcement, which fits best under M&A Activity (TAR) as it relates to merger proposals or takeover bids. The document length (8806 characters) and detailed description support this classification rather than a brief announcement or regulatory filing. Therefore, the appropriate classification is M&A Activity (TAR).
2020-12-22 English
News release - English.pdf
M&A Activity Classification · 95% confidence The document is a press release announcing Medicure Inc.'s acquisition of Marley Drug, including details about the transaction, the companies involved, and forward-looking statements. It does not contain financial statements, quarterly or annual results, or detailed financial analysis. It is not a report but an announcement of a corporate transaction (acquisition). This fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length is 7299 characters, sufficient for a detailed announcement but not a full report. Therefore, the classification is TAR with high confidence.
2020-12-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.